---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018276"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:48:08.430929+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q3 revenue down 25% to $8.0M, net loss widens; FY guidance reiterated

## Summary
- Total revenue $8.0M (-25% YoY); core business revenue $6.6M (-33%).
- Net loss $11.3M vs $6.4M loss in Q3 2022; EBITDA loss $12.9M vs $7.1M.
- Cell therapy revenue $4.7M (-40%); drug discovery $1.9M (-5%).
- FY2023 guidance reaffirmed: total $34-36M, core $28-30M, SPL ~$6M.
- Cash & investments $208.7M; expect ~$200M year-end.

## SEC filing metadata
- accession: 0001558370-23-018276
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837023018276/0001558370-23-018276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837023018276/mxct-20231108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018276
- JSON: https://secwatch.observer/filing/0001558370-23-018276.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018276.txt

## Key facts
- Earnings Releases
  MAXCYTE, INC. reported the third quarter ended September 30, 2023 results: revenue Total revenue of $8.0 million in the third quarter of 2023, net income Third quarter 2023 net loss was $11.3 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: Total revenue of $8.0 million in the third quarter of 2023
  - Net income: Third quarter 2023 net loss was $11.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications , today announced financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837023018276/0001558370-23-018276-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.